Oculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS)

Oculis Holding AG SEC filings continued to describe the OCS-01 DME program as on track for FDA submission after Phase 3 DIAMOND trials had already failed -- shares fell over 23% NEW YORK, June 1, 2026 /PRNewswire/ -- Investors in Oculis Holding AG (NASDAQ: OCS) lost approximately 23.4% of their holdings in a single session after the Company disclosed that its Phase 3 DIAMOND-1 and DIAMOND-2 trials for lead product OCS-01 failed to meet the primary endpoint in diabetic macular edema and that Oculis would not pursue an FDA filing for the indication. Shareholders who lost money on OCS are encouraged to submit their information to discuss their legal rights.